Janssen Announces New Three-Year TREMFYA ® (Guselkumab) Data Demonstrates Stably Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news